SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc -1.33%57.236.5%$169.22m
CTLTCatalent, Inc. -1.45%78.002.4%$132.70m
VRXValeant Pharmaceuticals International, Inc. 0.29%17.2014.1%$101.21m
JAZZJazz Pharmaceuticals Plc 1.08%106.602.4%$81.66m
UTHRUnited Therapeutics Corp. 0.45%117.4414.3%$68.96m
BHCBausch Health Cos., Inc. 0.29%17.200.0%$68.81m
ICPTIntercept Pharmaceuticals, Inc. 2.80%45.0916.8%$63.68m
PCRXPacira Biosciences, Inc. 0.49%57.8010.3%$55.61m
AXSMAxsome Therapeutics, Inc. 1.37%83.041.9%$51.78m
ZGNXZogenix, Inc. -2.05%27.247.5%$47.44m
PRGOPerrigo Co. Plc 1.68%55.176.8%$45.82m
MYOKMyoKardia, Inc. -0.29%92.861.8%$45.18m
ARGXargenx SE -1.04%250.510.0%$42.94m
GWPHGW Pharmaceuticals Plc -0.16%127.906.2%$38.07m
ICLRICON plc -2.48%169.964.3%$37.43m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.